Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

Item
http://www.wikidata.org/entity/Q34437208
EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Targeted therapies for gastric cancer: current status.Molecular targeting to treat gastric cancer.Genes and pathways driving glioblastomas in humans and murine disease models.Gefitinib therapy for advanced non-small-cell lung cancer.The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs.Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.STAT3 as a target for inducing apoptosis in solid and hematological tumorsPhase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells.Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.Increased activated Akt expression in renal cell carcinomas and prognosis.Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
P2860

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

Item
http://www.wikidata.org/entity/Q34437208
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@ast
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@en
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@nl
type
label
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@ast
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@en
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@nl
prefLabel
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@ast
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@en
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Pharmacodynamic studies with t ...... osine kinase inhibitor ZD1839.
@en
P2093
P304
P31
P356
10.1016/S0093-7754(01)90283-0
P433
P478
P50
P577
P698